drugset
drugset / Trial / NCT06574958

Clinical Study of CD38\CS1 Chimeric Antigen Receptor T Cells in the Treatment of Refractory/Recurrent Multiple Myeloma

NCT06574958 ↗

Phase 0 Active not recruiting 10 enrolled The Second Hospital of Shandong University
NaSingle-groupOpen-labelTreatment

Summary

The investigators developed a dual-target CAR-T targeting CD38 and CS1. Previous experimental results showed that the investigators double-target CAR-T not only had a good killing effect on CD38/CS1 double-positive tumor cells, but also had a high killing rate on CD38 or CS1 single-positive tumor cells. The investigators further study also found that the killing rate of the investigators dual-target CAR-T after mixing CD38 and CS1 monoyang tumor cells was over 80%. The advantage of the investigators dual-target CAR-T product is that the killing effect on single-yang, double-yang and single-yang mixed tumors is stable, and the killing rate is above 80% (see Figure 1). It has a wide killing range and can effectively reduce the phenomenon of tumor immune escape. Therefore, the investigators dual CAR products have good advantages and development potential.

Timeline

Start
2024-04-30
Primary completion
2025-01-15
Completion
2025-01-15

Drugs

EvaluationDrugModalityDoseRoute
Subject CD38/CS1 CAR T cells Cell therapy 40 ml Intravenous
Subject CD38/CS1 CAR T cells Cell therapy 1e+06 cells/kg Intravenous

Indications

No indication recorded.